

Special Issue

Innovative Drug Target Discovery in Cancer: From Molecular Mechanisms to Therapeutic Targets

Message from the Guest Editor

Cancer remains a leading cause of global mortality, with conventional therapies often limited by drug resistance and off-target toxicity. In recent decades, advances in molecular biology and genomics have provided new insights into the underlying mechanisms of cancer, offering promising avenues for drug discovery. The identification of novel molecular targets for cancer therapy is crucial for developing more effective and personalized treatment strategies. This Special Issue aims to curate high-impact research and reviews that illuminate novel cancer targets and the mechanistic foundations underpinning their therapeutic potential. Focus areas include the following:

- Molecular signaling pathways involved in cancer cell survival, proliferation, and metastasis.
- Identification and validation of novel molecular drug targets across various cancer types.
- Mechanisms of drug resistance and strategies to overcome resistance.
- Advances in high-throughput screening methods for drug discovery.
- Targeted therapies in cancer.
- Personalized medicine and biomarker-driven approaches in oncology.
- Emerging technologies in cancer drug discovery.

I look forward to receiving your contributions.

Guest Editor

Dr. Rakesh Nair

Department of Surgery, Division of Surgical Oncology, College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA

Deadline for manuscript submissions

31 December 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/256285

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).